BJC HealthCare Becomes First Health Care System in Midwest to Adopt Latest Robotic Technology for Arrhythmia Treatment
Tens of millions of individuals worldwide suffer from arrhythmias – abnormal heart rhythms that result when the heart beats too quickly, too slowly, or with an irregular pattern. When left untreated, certain arrhythmias can significantly increase the risk of stroke, heart failure, and sudden cardiac arrest. Robotic Magnetic Navigation introduces the benefits of robotic precision and safety to cardiac ablation, a common, minimally invasive procedure to treat arrhythmias.
The Genesis RMN system consists of two robotically controlled magnets, a flexible catheter with a magnetic tip, and an operating console. The system creates magnetic fields which can be finely manipulated to steer catheters with an unprecedented degree of precision and control. Because the catheter is controlled from the tip, it is flexible and gentle. With RMN, physicians can safely and effectively treat patients with complex arrhythmias, reaching areas of the heart that cannot be treated using traditional, manual techniques.
The clinical benefits of robotic cardiac ablation are well-documented with hundreds of publications describing, on average, fewer adverse events, better procedure success, and reduced radiation to patients with robotics when compared with manual cardiac ablation.
Today’s announcement continues the consistent collaboration in advancing clinical science, physician training, patient awareness, and patient access to robotic cardiac ablation procedures. Located less than one mile from Stereotaxis’ headquarters,
“We appreciate the opportunity to serve the patients of
About
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.
Stereotaxis Contacts:
Chairman and Chief Executive Officer
Chief Financial Officer
314-678-6100
investors@stereotaxis.com
Source: Stereotaxis, Inc.